Loading…
Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study
The outcome for patients with sepsis-associated acute kidney injury in the intensive care unit (ICU) remains poor. Low serum uromodulin (sUMOD) protein levels have been proposed as a causal mediator of this effect. We investigated the effect of different levels of sUMOD on the risk of sepsis and sev...
Saved in:
Published in: | Physiological genomics 2024-05, Vol.56 (5), p.409-416 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c327t-c943ed4010fb52f916ba868a77f05a55094c0488fa87d1e84bf076ce474651233 |
container_end_page | 416 |
container_issue | 5 |
container_start_page | 409 |
container_title | Physiological genomics |
container_volume | 56 |
creator | Eriksson, Mikael Lipcsey, Miklós Ilboudo, Yann Yoshiji, Satoshi Richards, Brent Hultström, Michael |
description | The outcome for patients with sepsis-associated acute kidney injury in the intensive care unit (ICU) remains poor. Low serum uromodulin (sUMOD) protein levels have been proposed as a causal mediator of this effect. We investigated the effect of different levels of sUMOD on the risk of sepsis and severe pneumonia and outcomes in these conditions. A two-sample Mendelian randomization (MR) study was performed. Single-nucleotide polymorphisms (SNPs) associated with increased levels of sUMOD were identified and used as instrumental variables for association with outcomes. Data from different cohorts were combined based on disease severity and meta-analyzed. Five SNPs associated with increased sUMOD levels were identified and tested in six datasets from two biobanks. There was no protective effect of increased levels of sUMOD on the risk of sepsis [two cohorts, odds ratio (OR) 0.99 (95% confidence interval 0.95-1.03),
= 0.698, and OR 0.95 (0.91-1.00),
= 0.060, respectively], risk of sepsis requiring ICU admission [OR 1.04 (0.93-1.16),
= 0.467], ICU mortality in sepsis [OR 1.00 (0.74-1.37),
= 0.987], risk of pneumonia requiring ICU admission [OR 1.05 (0.98-1.14),
= 0.181], or ICU mortality in pneumonia [OR 1.17 (0.98-1.39),
= 0.079]. Meta-analysis of hospital-admitted and ICU-admitted patients separately yielded similar results [OR 0.98 (0.95-1.01),
= 0.23, and OR 1.05 (0.99-1.12),
= 0.86, respectively]. Among patients with sepsis and severe pneumonia, there was no protective effect of different levels of sUMOD. Results were consistent regardless of geographic origins and not modified by disease severity.
The presence of acute kidney injury in severe infections increases the likelihood of poor outcome severalfold. A decrease in serum uromodulin (sUMOD), synthetized in the kidney, has been proposed as a mediator of this effect. Using the Mendelian randomization technique, we tested the hypothesis that increased sUMOD is protective in severe infections. Analyses, however, showed no evidence of a protective effect of higher levels of sUMOD in sepsis or severe pneumonia. |
doi_str_mv | 10.1152/physiolgenomics.00145.2023 |
format | article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_DiVA_org_uu_530452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3056793994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c327t-c943ed4010fb52f916ba868a77f05a55094c0488fa87d1e84bf076ce474651233</originalsourceid><addsrcrecordid>eNpdkU1P3DAQhq0KVCjtX6giuPTQbP0Z29wQbQEJ1Eu3V8tJJtQosYMdFy2_Hm8XOCCN5Dk8M_NaD0LHBK8IEfTb_HeTXBhvwYfJdWmFMeFiRTFl79AhEYzUlDZyr_RY81oxTg7Qh5TutpxU4j06YIo1WjfyEK3XMUyhz6PzVakEc3Kpsr4v7T-IUM0e8hS8s6eVrZaHUCc7zSNUN-B7GJ31VSx0CfJoFxfKhiX3m49of7Bjgk_P7xFa__zx-_yyvv51cXV-dl13jMql7jRn0HNM8NAKOmjStFY1yko5YGGFKPE7zJUarJI9AcXbAcumAy55Iwhl7Ah93e1NDzDn1szRTTZuTLDOfHd_zkyItyZnIxjmghb8yw6fY7jPkBYzudTBOFoPISdDNVVCcSF4QU_eoHchR18-YxgWjdRM6y11uqO6GFKKMLwmINhsXZk3rsx_V2brqgx_fj6R2wn619EXOewJejeVIA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3056793994</pqid></control><display><type>article</type><title>Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study</title><source>American Physiological Society:Jisc Collections:American Physiological Society Journals ‘Read Publish & Join’ Agreement:2023-2024 (Reading list)</source><creator>Eriksson, Mikael ; Lipcsey, Miklós ; Ilboudo, Yann ; Yoshiji, Satoshi ; Richards, Brent ; Hultström, Michael</creator><creatorcontrib>Eriksson, Mikael ; Lipcsey, Miklós ; Ilboudo, Yann ; Yoshiji, Satoshi ; Richards, Brent ; Hultström, Michael</creatorcontrib><description>The outcome for patients with sepsis-associated acute kidney injury in the intensive care unit (ICU) remains poor. Low serum uromodulin (sUMOD) protein levels have been proposed as a causal mediator of this effect. We investigated the effect of different levels of sUMOD on the risk of sepsis and severe pneumonia and outcomes in these conditions. A two-sample Mendelian randomization (MR) study was performed. Single-nucleotide polymorphisms (SNPs) associated with increased levels of sUMOD were identified and used as instrumental variables for association with outcomes. Data from different cohorts were combined based on disease severity and meta-analyzed. Five SNPs associated with increased sUMOD levels were identified and tested in six datasets from two biobanks. There was no protective effect of increased levels of sUMOD on the risk of sepsis [two cohorts, odds ratio (OR) 0.99 (95% confidence interval 0.95-1.03),
= 0.698, and OR 0.95 (0.91-1.00),
= 0.060, respectively], risk of sepsis requiring ICU admission [OR 1.04 (0.93-1.16),
= 0.467], ICU mortality in sepsis [OR 1.00 (0.74-1.37),
= 0.987], risk of pneumonia requiring ICU admission [OR 1.05 (0.98-1.14),
= 0.181], or ICU mortality in pneumonia [OR 1.17 (0.98-1.39),
= 0.079]. Meta-analysis of hospital-admitted and ICU-admitted patients separately yielded similar results [OR 0.98 (0.95-1.01),
= 0.23, and OR 1.05 (0.99-1.12),
= 0.86, respectively]. Among patients with sepsis and severe pneumonia, there was no protective effect of different levels of sUMOD. Results were consistent regardless of geographic origins and not modified by disease severity.
The presence of acute kidney injury in severe infections increases the likelihood of poor outcome severalfold. A decrease in serum uromodulin (sUMOD), synthetized in the kidney, has been proposed as a mediator of this effect. Using the Mendelian randomization technique, we tested the hypothesis that increased sUMOD is protective in severe infections. Analyses, however, showed no evidence of a protective effect of higher levels of sUMOD in sepsis or severe pneumonia.</description><identifier>ISSN: 1094-8341</identifier><identifier>ISSN: 1531-2267</identifier><identifier>EISSN: 1531-2267</identifier><identifier>DOI: 10.1152/physiolgenomics.00145.2023</identifier><identifier>PMID: 38369967</identifier><language>eng</language><publisher>United States: American Physiological Society</publisher><subject>acute kidney injury ; critical care ; Mendelian randomization ; Mortality ; Pneumonia ; Sepsis ; Single-nucleotide polymorphism ; uromodulin</subject><ispartof>Physiological genomics, 2024-05, Vol.56 (5), p.409-416</ispartof><rights>Copyright American Physiological Society May 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c327t-c943ed4010fb52f916ba868a77f05a55094c0488fa87d1e84bf076ce474651233</cites><orcidid>0000-0003-4675-1099 ; 0000-0003-4013-1446</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38369967$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-530452$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Eriksson, Mikael</creatorcontrib><creatorcontrib>Lipcsey, Miklós</creatorcontrib><creatorcontrib>Ilboudo, Yann</creatorcontrib><creatorcontrib>Yoshiji, Satoshi</creatorcontrib><creatorcontrib>Richards, Brent</creatorcontrib><creatorcontrib>Hultström, Michael</creatorcontrib><title>Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study</title><title>Physiological genomics</title><addtitle>Physiol Genomics</addtitle><description>The outcome for patients with sepsis-associated acute kidney injury in the intensive care unit (ICU) remains poor. Low serum uromodulin (sUMOD) protein levels have been proposed as a causal mediator of this effect. We investigated the effect of different levels of sUMOD on the risk of sepsis and severe pneumonia and outcomes in these conditions. A two-sample Mendelian randomization (MR) study was performed. Single-nucleotide polymorphisms (SNPs) associated with increased levels of sUMOD were identified and used as instrumental variables for association with outcomes. Data from different cohorts were combined based on disease severity and meta-analyzed. Five SNPs associated with increased sUMOD levels were identified and tested in six datasets from two biobanks. There was no protective effect of increased levels of sUMOD on the risk of sepsis [two cohorts, odds ratio (OR) 0.99 (95% confidence interval 0.95-1.03),
= 0.698, and OR 0.95 (0.91-1.00),
= 0.060, respectively], risk of sepsis requiring ICU admission [OR 1.04 (0.93-1.16),
= 0.467], ICU mortality in sepsis [OR 1.00 (0.74-1.37),
= 0.987], risk of pneumonia requiring ICU admission [OR 1.05 (0.98-1.14),
= 0.181], or ICU mortality in pneumonia [OR 1.17 (0.98-1.39),
= 0.079]. Meta-analysis of hospital-admitted and ICU-admitted patients separately yielded similar results [OR 0.98 (0.95-1.01),
= 0.23, and OR 1.05 (0.99-1.12),
= 0.86, respectively]. Among patients with sepsis and severe pneumonia, there was no protective effect of different levels of sUMOD. Results were consistent regardless of geographic origins and not modified by disease severity.
The presence of acute kidney injury in severe infections increases the likelihood of poor outcome severalfold. A decrease in serum uromodulin (sUMOD), synthetized in the kidney, has been proposed as a mediator of this effect. Using the Mendelian randomization technique, we tested the hypothesis that increased sUMOD is protective in severe infections. Analyses, however, showed no evidence of a protective effect of higher levels of sUMOD in sepsis or severe pneumonia.</description><subject>acute kidney injury</subject><subject>critical care</subject><subject>Mendelian randomization</subject><subject>Mortality</subject><subject>Pneumonia</subject><subject>Sepsis</subject><subject>Single-nucleotide polymorphism</subject><subject>uromodulin</subject><issn>1094-8341</issn><issn>1531-2267</issn><issn>1531-2267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdkU1P3DAQhq0KVCjtX6giuPTQbP0Z29wQbQEJ1Eu3V8tJJtQosYMdFy2_Hm8XOCCN5Dk8M_NaD0LHBK8IEfTb_HeTXBhvwYfJdWmFMeFiRTFl79AhEYzUlDZyr_RY81oxTg7Qh5TutpxU4j06YIo1WjfyEK3XMUyhz6PzVakEc3Kpsr4v7T-IUM0e8hS8s6eVrZaHUCc7zSNUN-B7GJ31VSx0CfJoFxfKhiX3m49of7Bjgk_P7xFa__zx-_yyvv51cXV-dl13jMql7jRn0HNM8NAKOmjStFY1yko5YGGFKPE7zJUarJI9AcXbAcumAy55Iwhl7Ah93e1NDzDn1szRTTZuTLDOfHd_zkyItyZnIxjmghb8yw6fY7jPkBYzudTBOFoPISdDNVVCcSF4QU_eoHchR18-YxgWjdRM6y11uqO6GFKKMLwmINhsXZk3rsx_V2brqgx_fj6R2wn619EXOewJejeVIA</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Eriksson, Mikael</creator><creator>Lipcsey, Miklós</creator><creator>Ilboudo, Yann</creator><creator>Yoshiji, Satoshi</creator><creator>Richards, Brent</creator><creator>Hultström, Michael</creator><general>American Physiological Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF2</scope><orcidid>https://orcid.org/0000-0003-4675-1099</orcidid><orcidid>https://orcid.org/0000-0003-4013-1446</orcidid></search><sort><creationdate>20240501</creationdate><title>Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study</title><author>Eriksson, Mikael ; Lipcsey, Miklós ; Ilboudo, Yann ; Yoshiji, Satoshi ; Richards, Brent ; Hultström, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c327t-c943ed4010fb52f916ba868a77f05a55094c0488fa87d1e84bf076ce474651233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>acute kidney injury</topic><topic>critical care</topic><topic>Mendelian randomization</topic><topic>Mortality</topic><topic>Pneumonia</topic><topic>Sepsis</topic><topic>Single-nucleotide polymorphism</topic><topic>uromodulin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eriksson, Mikael</creatorcontrib><creatorcontrib>Lipcsey, Miklós</creatorcontrib><creatorcontrib>Ilboudo, Yann</creatorcontrib><creatorcontrib>Yoshiji, Satoshi</creatorcontrib><creatorcontrib>Richards, Brent</creatorcontrib><creatorcontrib>Hultström, Michael</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Uppsala universitet</collection><jtitle>Physiological genomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eriksson, Mikael</au><au>Lipcsey, Miklós</au><au>Ilboudo, Yann</au><au>Yoshiji, Satoshi</au><au>Richards, Brent</au><au>Hultström, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study</atitle><jtitle>Physiological genomics</jtitle><addtitle>Physiol Genomics</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>56</volume><issue>5</issue><spage>409</spage><epage>416</epage><pages>409-416</pages><issn>1094-8341</issn><issn>1531-2267</issn><eissn>1531-2267</eissn><abstract>The outcome for patients with sepsis-associated acute kidney injury in the intensive care unit (ICU) remains poor. Low serum uromodulin (sUMOD) protein levels have been proposed as a causal mediator of this effect. We investigated the effect of different levels of sUMOD on the risk of sepsis and severe pneumonia and outcomes in these conditions. A two-sample Mendelian randomization (MR) study was performed. Single-nucleotide polymorphisms (SNPs) associated with increased levels of sUMOD were identified and used as instrumental variables for association with outcomes. Data from different cohorts were combined based on disease severity and meta-analyzed. Five SNPs associated with increased sUMOD levels were identified and tested in six datasets from two biobanks. There was no protective effect of increased levels of sUMOD on the risk of sepsis [two cohorts, odds ratio (OR) 0.99 (95% confidence interval 0.95-1.03),
= 0.698, and OR 0.95 (0.91-1.00),
= 0.060, respectively], risk of sepsis requiring ICU admission [OR 1.04 (0.93-1.16),
= 0.467], ICU mortality in sepsis [OR 1.00 (0.74-1.37),
= 0.987], risk of pneumonia requiring ICU admission [OR 1.05 (0.98-1.14),
= 0.181], or ICU mortality in pneumonia [OR 1.17 (0.98-1.39),
= 0.079]. Meta-analysis of hospital-admitted and ICU-admitted patients separately yielded similar results [OR 0.98 (0.95-1.01),
= 0.23, and OR 1.05 (0.99-1.12),
= 0.86, respectively]. Among patients with sepsis and severe pneumonia, there was no protective effect of different levels of sUMOD. Results were consistent regardless of geographic origins and not modified by disease severity.
The presence of acute kidney injury in severe infections increases the likelihood of poor outcome severalfold. A decrease in serum uromodulin (sUMOD), synthetized in the kidney, has been proposed as a mediator of this effect. Using the Mendelian randomization technique, we tested the hypothesis that increased sUMOD is protective in severe infections. Analyses, however, showed no evidence of a protective effect of higher levels of sUMOD in sepsis or severe pneumonia.</abstract><cop>United States</cop><pub>American Physiological Society</pub><pmid>38369967</pmid><doi>10.1152/physiolgenomics.00145.2023</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4675-1099</orcidid><orcidid>https://orcid.org/0000-0003-4013-1446</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1094-8341 |
ispartof | Physiological genomics, 2024-05, Vol.56 (5), p.409-416 |
issn | 1094-8341 1531-2267 1531-2267 |
language | eng |
recordid | cdi_swepub_primary_oai_DiVA_org_uu_530452 |
source | American Physiological Society:Jisc Collections:American Physiological Society Journals ‘Read Publish & Join’ Agreement:2023-2024 (Reading list) |
subjects | acute kidney injury critical care Mendelian randomization Mortality Pneumonia Sepsis Single-nucleotide polymorphism uromodulin |
title | Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T07%3A58%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Uromodulin%20in%20sepsis%20and%20severe%20pneumonia:%20a%20two-sample%20Mendelian%20randomization%20study&rft.jtitle=Physiological%20genomics&rft.au=Eriksson,%20Mikael&rft.date=2024-05-01&rft.volume=56&rft.issue=5&rft.spage=409&rft.epage=416&rft.pages=409-416&rft.issn=1094-8341&rft.eissn=1531-2267&rft_id=info:doi/10.1152/physiolgenomics.00145.2023&rft_dat=%3Cproquest_swepu%3E3056793994%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c327t-c943ed4010fb52f916ba868a77f05a55094c0488fa87d1e84bf076ce474651233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3056793994&rft_id=info:pmid/38369967&rfr_iscdi=true |